S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
NASDAQ:JSPR

Jasper Therapeutics (JSPR) Stock Price, News & Analysis

$30.00
+1.18 (+4.09%)
(As of 09:34 AM ET)
Today's Range
$29.98
$30.00
50-Day Range
$10.80
$29.67
52-Week Range
$4.00
$30.28
Volume
3,740 shs
Average Volume
129,759 shs
Market Capitalization
$451.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.50

Jasper Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
116.9% Upside
$62.50 Price Target
Short Interest
Healthy
2.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Jasper Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$4.53 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.00) to ($4.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

370th out of 939 stocks

Biological Products, Except Diagnostic Industry

52nd out of 154 stocks

JSPR stock logo

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

JSPR Stock Price History

JSPR Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
JSPR Jul 2024 40.000 call
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
JSPR Oct 2024 30.000 call
JSPR Oct 2024 17.500 call
JSPR Apr 2024 35.000 call
JSPR Mar 2024 22.500 put
JSPR Mar 2024 15.000 put
Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)
JSPR Mar 2024 20.000 call
JSPR Jul 2024 22.500 call
See More Headlines
Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
3/27/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:JSPR
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$62.50
High Stock Price Target
$80.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+116.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-64,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.03 per share

Miscellaneous

Free Float
14,477,000
Market Cap
$434.03 million
Optionable
Optionable
Beta
2.18
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ronald A. Martell (Age 62)
    President, CEO & Director
    Comp: $892.45k
  • Dr. Judith Anne Shizuru M.D. (Age 68)
    Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
    Comp: $291.25k
  • Mr. Jeetinder Singh Mahal M.B.A. (Age 52)
    Chief Operating Officer
    Comp: $579.46k
  • Mr. Herbert C. Cross (Age 52)
    CFO & Corporate Secretary
  • Dr. Luca Di Noto Ph.D.
    Senior Vice President of Technical Operations
  • Mr. David Ku M.D.
    Vice President of Corporate Development, Portfolio Strategy & Management
  • Mr. Matthew Ford
    Vice President of Human Resources
  • Dr. Wendy Pang M.D.
    Ph.D., Senior Vice President of Research & Translational Medicine
  • Dr. Edwin Jonathan Tucker M.D. (Age 52)
    Chief Medical Officer
  • Ms. Patricia Carlos
    Senior Vice President of Regulatory Affairs & Quality

JSPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings
or view top-rated stocks.

What is Jasper Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued twelve-month price objectives for Jasper Therapeutics' stock. Their JSPR share price targets range from $40.00 to $80.00. On average, they anticipate the company's share price to reach $62.50 in the next year. This suggests a possible upside of 116.9% from the stock's current price.
View analysts price targets for JSPR
or view top-rated stocks among Wall Street analysts.

How have JSPR shares performed in 2024?

Jasper Therapeutics' stock was trading at $7.89 on January 1st, 2024. Since then, JSPR stock has increased by 265.3% and is now trading at $28.82.
View the best growth stocks for 2024 here
.

Are investors shorting Jasper Therapeutics?

Jasper Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 327,300 shares, an increase of 13.3% from the February 29th total of 288,900 shares. Based on an average daily volume of 128,000 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.8% of the company's shares are sold short.
View Jasper Therapeutics' Short Interest
.

When is Jasper Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our JSPR earnings forecast
.

How were Jasper Therapeutics' earnings last quarter?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) issued its quarterly earnings data on Monday, March, 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.15.

When did Jasper Therapeutics' stock split?

Jasper Therapeutics's stock reverse split before market open on Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (36.68%), Vanguard Group Inc. (36.68%), Opaleye Management Inc. (35.72%), Kingdon Capital Management L.L.C. (31.72%), Sphera Funds Management LTD. (6.39%) and Fernwood Investment Management LLC (4.43%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans, Velan Capital Investment Manag and William Lis.
View institutional ownership trends
.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JSPR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners